1520-6017/asset/JPS_left.gif?v=1&s=becd26fac43b87042ad04af68bbe20d6a12e64fc)
1520-6017/asset/olbannerright.jpg?v=1&s=254f44b422de0f476861bd1056a1789033e2171c)
Research Article
Controlled-release isosorbide dinitrate pellets. Part II: In vivo studies
Article first published online: 17 SEP 2006
DOI: 10.1002/jps.2600821224
Copyright © 1993 Wiley-Liss, Inc., A Wiley Company
1520-6017/asset/cover.gif?v=1&s=e589ccf35fd012c675e943835781318cb8666bed "Journal of Pharmaceutical Sciences")
Total views since August 2010: 5
Additional Information
How to Cite
Lalla, J. K., Bhat, S. U. and Girappanavar, D. M. (1993), Controlled-release isosorbide dinitrate pellets. Part II: In vivo studies. J. Pharm. Sci., 82: 1292–1295. doi: 10.1002/jps.2600821224
Publication History
- Issue published online: 17 SEP 2006
- Article first published online: 17 SEP 2006
- Manuscript Accepted: 25 FEB 1993
- Manuscript Received: 7 OCT 1991
Abstract
Isosorbide dinitrate (ISDN) capsules containing 20.0 and 40.0 mg of the drug (reported earlier in Part I of this series) were evaluated in vivo in eight healthy volunteers in a double-blind study with marketed sustained-release preparations containing 20.0 and 40.0 mg of ISDN. The results were normalized by administering placebo and four conventional ISDN tablets, each containing 5.0 mg of ISDN, to the same group of volunteers in a separate study. The blood pressure of the volunteers was monitored for 8 h. The results indicate that the capsules prepared in the laboratory with the new formulation gave controlled release when compared with the respective marketed SR product.